Brain peptide hydrolysate-containing beverage composition for improving brain function as well as preparation method and application of brain peptide hydrolysate-containing beverage composition

Abstract

The invention provides a brain-function-improving brain-peptide-hydrolysate-containing beverage composition as well as a preparation method and application thereof, and relates to the technical field of peptide beverages and medicines. The brain protein zymolyte concentrated solution, the walnut peptide and the intestinal peptide are compatible, and the dosage is optimized, so that the beverage composition is fully absorbed, better helps to activate the nervous system, improve the excitability of brain cells, stimulate the growth and growth of neuronal synapses, help the repair of brain nerves, enhance gastrointestinal motility, better protect gastrointestinal mucosa and improve the immunity of the brain. The traditional Chinese medicine is especially suitable for patients with weakness of the spleen and the stomach.

Description

Technical Field

[0001] The present invention relates to the technical field of peptide drinks and medicines, and in particular to a drink composition containing brain peptide hydrolysate for improving brain function, and a preparation method and application thereof. Background Art

[0002] Brain injury is the damage to brain tissue caused by trauma to the head and face; the most common clinical symptoms include headache, impaired consciousness, and head hemorrhage, which generally require conservative treatment or surgical treatment. The prognosis of mild patients is still good, while severe patients often have varying degrees of neurological deficits (limb paralysis, slurred speech, sensory impairment, etc.), and the prognosis is poor.

[0003] The prognosis of brain trauma and the severity of the injury are closely related to factors such as the patient's age, health status, timely treatment and rehabilitation measures. Generally speaking, the prognosis of mild brain trauma is more optimistic, while the prognosis of severe brain trauma is more severe. The prognosis of mild brain trauma is usually good, and patients can often recover completely after receiving appropriate treatment. Mild brain trauma generally manifests as a brief loss of consciousness after head injury or symptoms such as headache and dizziness, and usually does not leave obvious sequelae. The prognosis of severe brain trauma is often more complicated. Severe brain trauma may have long-term effects on the patient's physical and cognitive functions. Patients with severe brain trauma may experience long-term loss of consciousness, memory loss, language disorders, limb disability and other serious sequelae; at this time, the patient may need comprehensive rehabilitation treatment and long-term care.

[0004] Peptides are important components of the brain's tissue structure and can provide raw materials for the physiological activities of brain cells; however, most of the peptides commonly used are whole peptides, which often have problems with poor effects and difficulty in digestion during use by patients; whole peptides are hydrolyzed into small molecule peptides, which are unstable and have poor absorption and therapeutic effects if consumed in large quantities. For those with weak spleen and stomach, they may even experience symptoms such as indigestion, dry stools and constipation. Summary of the invention

[0005] The present invention provides a beverage composition containing brain peptide hydrolysate for improving brain function, a preparation method and an application thereof. On the one hand, the provided beverage composition containing brain peptide hydrolysate for improving brain function provides rich nutrients for the recovery of brain function, and the brain peptide hydrolysate small molecules in the composition are relatively stable. The composition containing brain peptides has a reasonable formula and is easy to absorb, the recovery of brain function is fast, and the gastrointestinal absorption burden is small. On the other hand, the present application provides a beverage composition containing brain peptide hydrolysate for improving brain function, a preparation method and an application thereof. The prepared brain peptide beverage composition has good stability, is easy to absorb, and can be used to treat brain damage.

[0006] Technical solution: In the first aspect, the present application provides a beverage composition containing brain peptide hydrolysate for improving brain function: A brain peptide hydrolyzate beverage composition for enhancing brain function, characterized in that, based on the total mass of the beverage composition, it comprises 1-12 wt% of brain protease hydrolyzate concentrate; 0.1-2 wt% of walnut peptide; 0.01-0.1 wt% of intestinal peptide; 1-8 wt% of stabilizer; 1-7 wt% of concentrated fruit juice; 0.1-2 wt% of auxiliary materials, wherein the auxiliary materials include one or several combinations of wild jujube seed composite powder, γ-aminobutyric acid and taurine; 0.03-0.2 wt% of additives, wherein the additives include one or several combinations of preservatives, flavor regulators, stabilizers, and fragrances; and the balance of water.

[0007] Brain peptides can help activate the nervous system, increase the excitability of brain cells, and are helpful for the repair of brain nerves. Peptides have a certain effect on activating the nervous system. Therefore, when there is brain nerve damage, peptides need to be supplemented during the repair process, which helps to accelerate the recovery of nerve function; at the same time, brain peptides are rich in lipids and unsaturated fatty acids, which are important components of the brain, and peptides can promote the repair of brain nerves.

[0008] Intestinal peptide concentrate is a biological product produced by using pig intestine as raw material and biological extraction technology, which has the function of regulating gastrointestinal digestion and absorption. Its main components are a mixture of active intestinal peptides, amino acids, and intestinal polysaccharides (glycosaminoglycans GAGs). The concentration of active substances is higher and the molecular weight is smaller, making it easier to be ingested and absorbed by the human body in large amounts; intestinal peptides can regulate gastrointestinal function. Vasoactive intestinal peptide belongs to a neurotransmitter and has a dual regulatory effect in the body. In the digestive system, it can promote the relaxation of intestinal smooth muscle, and at the same time relax the lower esophageal sphincter, intestinal smooth muscle and other muscles. In the nervous system, it can dilate blood vessels, increase blood flow, and can also dilate tracheal and bronchial smooth muscles.

[0009] Walnut peptide can stimulate the growth and elongation of nerve synapses and help the repair of brain nerves; when brain cells carry out physiological activities, they require a certain amount of energy consumption, and walnut peptide can also provide sufficient energy; the combination of brain peptides can better promote the development of brain cells and help the repair of brain nerves.

[0010] In this application, a hydrolyzed cerebroprotease hydrolyzate concentrate is used. The brain peptides are preferably small molecule peptides, which is beneficial to the full absorption of the beverage composition. In addition, enteropeptides are added. Enteropeptides can improve the digestive function of the stomach and intestines, better protect and repair damaged gastrointestinal mucosa, enhance gastrointestinal motility, promote the absorption of polypeptides by the intestines, and accelerate the recovery of brain injuries, without increasing the burden on the spleen and stomach, especially suitable for those with weak spleen and stomach.

[0011] Further, the beverage composition, based on the total mass of the beverage composition, includes cerebroprotease hydrolyzate concentrate 3 - 10 wt%; walnut peptide 0.5 - 1.5 wt%; enteropeptide 0.01 - 0.05 wt%; stabilizer 3 - 5 wt%; concentrated fruit juice 3 - 5 wt%; auxiliary materials 0.5 - 1.5 wt%, additives 0.08 - 0.12 wt%, and the balance of water.

[0012] Further, the content of taurine in the solid content of the beverage composition is less than 1 wt%; the mass ratio of the enteropeptide to taurine is (0.13 - 1.67):1.

[0013] Further, the mass ratio of γ-aminobutyric acid to taurine is (10 - 20):1.

[0014] Further, the mass ratio of the enteropeptide to taurine is (0.2 - 1):1.

[0015] Further, the auxiliary materials include 0.3 - 0.5 wt% of wild jujube seed compound powder, 0.4 - 0.6 wt% of γ-aminobutyric acid and 0.02 - 0.06 wt% of taurine; the additives are composed of 0.05 - 0.12 wt% of food flavor, 0.015 - 0.021 wt% of nisin and 0.003 - 0.009 wt% of sucralose.

[0016] Further, the concentrated fruit juice includes one or a combination of blueberry concentrated juice, apple concentrated juice, and lemon concentrated juice; The cerebroprotease hydrolyzate concentrate includes amino acids with a sequence such as Leu-Phe-Leu-Pro-Arg.

[0017] Further, the stabilizer is composed of 2 - 5 wt% of erythritol and 0.06 - 0.1 wt% of xanthan gum.

[0018] Further, the cerebroprotease hydrolyzate concentrate includes amino acids with a sequence such as Leu-Phe-Leu-Pro-Arg.

[0019] Furthermore, the beverage composition, based on the total mass of the beverage composition, includes Encephaloprotein hydrolysate concentrate 6 wt%; Walnut peptide 1.04 wt%; Enteropeptide 0.02 wt%; Stabilizer: The stabilizer consists of erythritol 4 wt% and xanthan gum 0.08 wt%; Concentrated fruit juice: Blueberry concentrated juice 4 wt%; Excipients: The excipients consist of wild jujube seed composite powder 0.4 wt%, γ-aminobutyric acid 0.5 wt% and taurine 0.05 wt%; Additives: The additives consist of food flavor 0.08 wt%, nisin 0.019 wt% and sucralose 0.006 wt%; The balance is water.

[0020] In a second aspect, the present application provides a method for preparing a brain function-enhancing beverage composition containing brain peptide hydrolysate.

[0021] In a third aspect, the present application provides an application of a brain function-enhancing beverage composition containing brain peptide hydrolysate in functional beverages and / or pharmaceuticals for the treatment of brain injuries.

[0022] Beneficial effects: 1. The present application uses encephaloprotein hydrolysate concentrate, walnut peptide and enteropeptide in combination and optimizes their dosages, so that the beverage composition can be fully absorbed, which helps to activate the nervous system, improve the excitability of brain cells, stimulate the growth and elongation of nerve synapses, help repair brain nerves, and at the same time enhance gastrointestinal motility, protect and repair gastrointestinal mucosa well, and reduce the burden on the spleen and stomach, especially suitable for patients with weak spleen and stomach.

[0023] 2. Further, taurine can quickly improve the activity of brain cells and memory; however, excessive intake also has harms such as damaging the gastrointestinal mucosa, causing insomnia, and increasing blood pressure; γ-aminobutyric acid can promote sleep, relieve stress, improve cognitive function, enhance immunity and improve overall health; in the excipients of the present application, γ-aminobutyric acid and taurine are used in combination synergistically, and encephaloprotein hydrolysate and walnut peptide can repair brain nerves well. By optimizing their dosages, it helps to repair brain nerves, does not increase the burden on the spleen and stomach, and has little irritation to the gastrointestinal mucosa, being suitable for patients with weak spleen and stomach.

[0024] 3. Further, the stabilizer uses erythritol, a small molecule alcohol, and xanthan gum, a large molecule polysaccharide, in combination and with optimized dosages. The small molecule and the large molecule form a good compatibility effect, and the interaction between the two is small, which stabilizes the small molecule peptides in the brain protease hydrolyzate concentrate well, thereby improving the stability of the small peptide segments and enhancing the effect of the beverage composition in repairing the brain nerves. Detailed implementation manners

[0025] To make the technical solutions of the present invention clearer, the following further describes the present invention in detail with reference to specific embodiments.

[0026] Preparation Example 1, a brain protease hydrolyzate concentrate, the preparation process is as follows: Step 1: Take out fresh pig brains or thawed frozen pig brains, wash them with purified water, and remove the fascia and blood vessels; after mixing the pig brains with purified water at a ratio of 1:1.5, grind them into a homogeneous slurry with a colloid mill. After the tissue is basically broken, adjust it to a finer fineness. The grinding and homogenization cycle is 5 min / batch, and then add purified water 1.3 times the amount of the homogenate and continue homogenizing for 5 min. Mix the homogenized brain slurry of each batch evenly, and adjust the pH value to 9.5 with potassium hydroxide solution; the coarsest mesh size is 100 mesh; the finer mesh size is 150 mesh; Step 2: Place the adjusted brain slurry homogenate in a microwave tank with a stirring device, control the temperature at 60 °C, microwave for 20 min, and keep warm for 15 min; the frequency of the microwave tank is 3300 MHZ and the power is 25 KW; discharge the homogenate after microwave treatment, and centrifuge the protein and lipid twice at 38 °C with a butterfly high-speed centrifuge. For the first centrifugation, control the discharged light liquid to be 42%. After discharging the light liquid, microwave for 20 min and then perform the second centrifugation. The light liquid obtained from the second centrifugation is the phospholipid solution. Mix the thick liquids obtained from the two centrifugations; the rotation speed of the first centrifugation is 9000 r / min; the rotation speed of the second centrifugation is 12000 r / min; the temperature of the homogenate during the second centrifugation is not lower than 38 °C; Step 3: Adjust the pH value of the mixed thick liquid obtained in Step 2 to 5.0 with dilute hydrochloric acid to make the protein precipitate in a large cloud-like shape and separate into layers. Then, use a 250-mesh filter cloth centrifuge to remove the liquid, and collect the filter residue to obtain brain separated protein; dissolve the collected filter residue with purified water 2 times the amount of the wet filter residue to obtain a 5% solution, adjust the pH value to 9.0, and then add trypsin (5000 u / g) at 4.5% of the mass of the separated protein and continue homogenizing and circulating; when the pH value drops to about 7.5 again, add alkali to adjust it to 8.6 and then circulate for 3 minutes, and discharge the slurry; Step 4: Feed the slurry obtained in Step 3 into a microwave pre-detection to measure the pH value. When the pH value is less than 7, add alkali to adjust the pH value to 8.2, carry out microwave-assisted enzymatic hydrolysis, keep warm for 15 min, and inactivate the enzyme; Drain the inactivated enzymatic hydrolysate. When the temperature of the enzymatic hydrolysate drops below 40 °C, add a 1.5% chitosan solution dissolved in 15% acetic acid under stirring conditions, adjust the pH value to 4.8, and precipitate the unhydrolyzed brain proteins, phospholipids and other macromolecular impurities; Centrifuge and filter the precipitate with a 200-mesh filter cloth to remove the precipitate; Filter the centrifugate with a 0.25-μm hollow fiber membrane, and filter the filtrate with an ultrafiltration membrane that can intercept a molecular weight of 10,000 Da. The permeate is the porcine brain polypeptide solution. If only polypeptides are made, this solution is concentrated under reduced pressure and then freeze-dried to obtain polypeptide powder; Step 5: Filter the polypeptide solution with a nanofiltration membrane that intercepts a molecular weight of 1200 Da, concentrate the filtrate with a reverse osmosis membrane, freeze the concentrated solution, and dry it to obtain a brain protease hydrolyzate concentrate with a solid content of 55 wt%, wherein the content of small molecule peptides in the brain protein hydrolyzate is 80 wt%, the nitrogen content of the dry matter is 14.5%, and the fat content is 0.6%.

[0027] Use LC-MS / MS to determine the amino acid sequence and molecular weight in the brain protease hydrolyzate concentrate. Before the sample is loaded onto the machine, reduction alkylation and desalting treatments are first carried out. The pre-column of the capillary liquid chromatography column used is an Acclaim PepMap RP LC C18 analytical column (5 μm) with a size of 300 μm × 5 mm, and the analytical column is an Acclaim PepMap RP LC C18 analytical column (1.9 μm) with a size of 150 μm × 150 mm. Mobile phase A is a 0.1% (v / v) formic acid solution and a 2% (v / v) acetonitrile solution, and mobile phase B is a 0.1% (v / v) formic acid solution and an 80% (v / v) acetonitrile solution. The flow rate is 600 nL / min, and the analysis time for each component is 60 min.

[0028] The MS and MS / MS parameters are as follows: (1) MS parameters: Resolution is 70,000; Maximum injection time is 40 ms; Scanning range is 300 - 1400 m / z.

[0029] (2) MS / MS parameters: Resolution is 175,000; Maximum injection time is 60 ms; Scanning range is 300 - 1400 m / z; TopN = 20; NCE / steepedNCE = 27.

[0030] Analyze the original MS / MS file with Mascot software according to the sample type and search and compare it with the Uniprot database (https: / / www.uniprot.org / ) Susscrofa (Pig) to determine the amino acid sequence of the peptide.

[0031] After the R4 component is retrieved by mass spectrometry data, the screening criteria for peptide segments, sites, and protein identification are PSMFDR ≤ 0.01 and ProteinFDR ≤ 0.01 respectively, and the amino-terminal sequence of the peptide segment is obtained. The cerebroprotease hydrolyzate concentrate includes amino acids with a sequence such as Leu-Phe-Leu-Pro-Arg.

[0032] The cerebroprotease hydrolyzate concentrate can also be purchased. For example, if it is prepared by Shaoxing Jiayun Biotechnology Co., Ltd., the content of small molecule peptides is 40-90 wt%.

[0033] Example 1, a brain function-enhancing drink composition containing cerebropeptide hydrolyzate, uses the raw materials as shown in Table 1, and the preparation process is as follows: After mixing the raw materials used, at a temperature of 25 °C (in other examples, any temperature selected from 15 °C - 30 °C), stir at 300 r / min for 40 min (in other examples, any stirring speed selected from 200 - 500 r / min and any stirring time selected from 30 - 50 min), and a drink composition containing cerebropeptide hydrolyzate is prepared.

[0034] The cerebroprotease hydrolyzate concentrate uses the cerebroprotease hydrolyzate concentrate of Preparation Example 1; walnut peptide: walnut small molecule peptide, with a molecular weight less than 1000 Da, solubility > 90%, and moisture < 5%; intestinal peptide: molecular weight less than 1000 Da, solubility > 90%, and moisture < 6%.

[0035] Suanzaoren composite powder, 120 mesh, purity 98%; xanthan gum, average molecular weight 2 million, purity 98%.

[0036] Examples 2 to 5, a brain function-enhancing drink composition containing cerebropeptide hydrolyzate, is different from Example 1 in that the types and weight settings of the raw materials used are different, as specifically shown in Table 1.

[0037] Table 1. List of types and weights of raw materials used in the drink compositions of Examples 1 to 5

[0038]

[0039] Examples 5 to 10, a brain function-enhancing drink composition containing cerebropeptide hydrolyzate, is different from Example 1 in that the weight settings of the intestinal peptide and taurine used are different, as specifically shown in Table 2.

[0040] Table 2. Dosages of intestinal peptide and taurine used in the drink compositions of Examples 5 to 10 and Example 1 Raw materials Example 1 Example 6 Example 7 Example 8 Example 9 Example 10 Percentage of taurine in solid content / wt% 0.31% 0.12% 0.92% 1.22% 1.52% 1.47% Mass ratio of γ-aminobutyric acid to taurine 10:1 25:1 3.33:1 2.5:1 2:1 4:1 Mass ratio of enteropeptide to taurine 0.4:1 1:1 0.13:1 0.1:1 0.2:1 0.4:1 Enteropeptide / wt% 0.02 0.02 0.02 0.02 0.05 0.1 Taurine / wt% 0.05 0.02 0.15 0.2 0.25 0.25 Example 11. A brain peptide hydrolyzate-containing drink composition for enhancing brain function, which is different from Example 1 in that the wild jujube seed composite powder replaces γ-aminobutyric acid and taurine in equal amounts.

[0041] Example 12. A brain peptide hydrolyzate-containing drink composition for enhancing brain function, which is different from Example 1 in that erythritol replaces xanthan gum in equal amounts.

[0042] Example 13. A brain peptide hydrolyzate-containing drink composition for enhancing brain function, which is different from Example 1 in that xanthan gum replaces erythritol in equal amounts.

[0043] Comparative Example 1. A brain peptide hydrolyzate-containing drink composition for enhancing brain function, which is different from Example 1 in that enteropeptide replaces walnut peptide in equal amounts.

[0044] Comparative Example 2. A brain peptide hydrolyzate-containing drink composition for enhancing brain function, which is different from Example 1 in that walnut peptide replaces enteropeptide in equal amounts.

[0045] Experimental performance: C57 mice (18 - 24 g), male, 10 mice in each group. The dosage is 20 mg / kg each time. The drug is administered by gavage after modeling (using Examples and Comparative Examples respectively). The normal group and the control group are gavaged with the same volume of normal saline; once a day for 2 weeks.

[0046] Preparation of craniocerebral injury model: After anesthetizing the mice with chloral hydrate, they are fixed on a stereotaxic apparatus, the hair is shaved, the scalp is cut open to expose the skull, and a circular hole with a diameter of 4 mm is made in the left cerebral hemisphere to expose the brain tissue, and a free-fall striker is used for striking to establish a craniocerebral injury model. In the normal group, the skull is opened without any operation. In the control group, only striking is performed without administering drugs. In the drug treatment group, the corresponding drug is administered by gavage after striking; the mice after drug administration are placed on a cage rack with filter paper laid in the cage, and the number of fecal pellets and the quality of feces of the mice are observed and recorded every day.

[0047] Measurement of the degree of brain edema: After the animals are sacrificed, the brain tissue is collected and weighed, denoted as wet weight (WW). Then the brain tissue is dried in an oven at 110 °C for 24 h and weighed, denoted as dry weight (DW). Water content (%) = (WW - DW) / WW × 100%.

[0048] The measurement results of the water content of the brain tissue are shown in Table 3.

[0049] Results of behavioral tests: The balance fatigue rotarod experiment is used to measure the latency time for the mice to fall from the rotating rod, that is, The time of persistence on the rotating rod; the balance beam experiment records the number of missteps of the mice on the balance beam, and this experiment is mainly used to evaluate the sensorimotor ability of animals after injury.

[0050] Determination of inflammation level: The levels of inflammatory factors (TNF-α and IL-1β) in the brain tissue were detected using an ELISA enzyme-linked immunosorbent assay kit, and the experimental operations were carried out according to the kit instructions.

[0051] Table 3. Experimental results of Examples 1 to 13, Comparative Example 1, Comparative Example 2, the normal group, and the control group Differentiation Average number of defecations per day (pieces) Average daily defecation volume (g) Brain tissue water content / % Rotarod test (fall latency, s) Balance beam test (number of missteps) TNF-α (pg / mg protein) IL-1β (pg / mg protein) Normal group 42.4±0.82 0.8±0.04 73.5±3.3 186.6±10.7 0.2±0.3 410.3±51.2 82.1±8.5 Control group 33.6±1.35 0.4±0.08 91.6±4.6 33.5±15.8 3.6±0.7 754.5±58.4 161.7±31.6 Example 1 38.8±0.95 0.6±0.05 82.4±3.0 123.3±10.7 1.3±0.3 532.9±53.3 105.6±10.8 Example 2 38.2±0.97 0.5±0.05 85.8±3.6 111.3±12.4 1.5±0.5 556.6±55.8 118.3±13.4 Example 3 37.8±0.97 0.4±0.07 86.3±3.9 109.5±13.6 1.7±0.6 581.3±50.6 120.6±15.2 Example 4 36.9±0.97 0.4±0.07 87.3±3.8 96.4±12.3 1.9±0.8 642.4±53.5 123.8±13.4 Example 5 37.5±0.97 0.4±0.07 87.5±3.4 98.5±13.8 2.2±1.0 623.5±53.8 125.1±14.7 Example 6 39.3±0.95 0.6±0.08 79.7±3.2 118.5±10.8 1.4±0.6 535.8±54.3 106.8±11.2 Example 7 35.5±0.95 0.5±0.05 83.2±3.1 125.6±9.8 1.0±0.6 546.9±55.1 116.9±11.6 Example 8 34.3±0.95 0.5±0.06 83.9±3.0 130.3±11.6 0.9±0.5 548.9±53.5 118.2±10.5 Example 9 35.1±0.95 0.6±0.09 84.4±3.2 131.5±10.5 0.7±0.4 540.9±52.4 116.8±11.2 Example 10 35.8±0.95 0.6±0.05 84.3±3.1 132.3±10.9 0.6±0.5 536.2±51.9 108.9±10.6 Example 11 37.0±0.80 0.62±0.06 88.5±3.3 95.4±9.8 2.0±0.3 652.7±56.3 127.5±10.5 Example 12 38.0±0.90 0.59±0.05 85.5±3.1 115.3±10.7 1.8±0.4 566.7±53.4 112.2±10.8 Example 13 38.2±0.91 0.61±0.05 84.1±3.0 118.5±10.2 1.5±0.3 570.5±52.2 109.3±10.5 Comparative Example 1 40.6±0.90 0.60±0.07 87.0±3.2 93.5±10.2 3.5±0.4 585.4±52.2 130.5±10.6 Comparative Example 2 33.9±0.93 0.60±0.05 89.3±3.9 126.5±13.5 1.2±0.6 676.3±50.2 145.3±15.1 It can be seen from Examples 1, 5 to 10 that as the content of taurine increases, the average number of daily defecation pellets of the mice decreases, and the cerebral edema and inflammation of the mice show an increasing trend. However, the rotating rod experiment and the balance beam experiment have good experimental results, indicating that the repair effect of the brain nerves is better. In summary, when the content of taurine in the solid content of the beverage composition is less than 1 wt%; the mass ratio of γ-aminobutyric acid to taurine is (10 - 20):1; the mass ratio of enteropeptide to taurine is (0.2 - 1):1, it has a better comprehensive effect, the repair effect of the brain nerves is better, and at the same time, it does not increase the burden on the spleen and stomach and has little irritation to the gastrointestinal mucosa.

[0052] The above-described embodiments merely represent several implementation manners of the present invention. The description is relatively specific and detailed, but it should not be construed as a limitation on the scope of the present invention patent. It should be noted that for those of ordinary skill in the art, without departing from the concept of the present invention, several modifications and improvements can still be made, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the present invention patent shall be subject to the appended claims.

Claims

1. A beverage composition containing brain peptide hydrolysate for improving brain function, characterized in that: The total amount of the beverage composition is as follows: Brain protein hydrolysate concentrate 1-12wt%; Walnut peptide 0.1-2wt%; Intestinal peptide 0.01-0.1wt%; Stabilizer 1-8wt%; Concentrated juice 1-7wt%; Auxiliary materials 0.1-2wt%, Wherein, the auxiliary materials include one or a combination of Suanzaorensis seed composite powder, γ-aminobutyric acid and taurine; Additives 0.03-0.2wt%, Wherein, the additives include one or a combination of preservatives, flavor regulators, stabilizers, and flavors; and the remaining water.

2. The brain function-enhancing beverage composition containing brain peptide hydrolysate according to claim 1, characterized in that: The total amount of the beverage composition is as follows: Brain protein hydrolysate concentrate 3-10wt%; Walnut peptide 0.5-1.5wt%; Intestinal peptide 0.01-0.05wt%; Stabilizer 3-5wt%; Concentrated juice 3-5wt%; Auxiliary materials 0.5-1.9wt%, Additives 0.08-0.12wt%, and the remaining water.

3. The brain function-enhancing beverage composition containing brain peptide hydrolysate according to claim 2, characterized in that: The content of taurine in the solid content of the beverage composition is less than 1wt%; the mass ratio of the intestinal peptide to taurine is (0.13-1.67):

1.

4. The brain function-enhancing beverage composition containing brain peptide hydrolysate according to claim 3, characterized in that: The mass ratio of γ-aminobutyric acid to taurine is (10-20):

1.

5. The brain function-enhancing beverage composition containing brain peptide hydrolysate according to claim 3, characterized in that: The mass ratio of the intestinal peptide to taurine is (0.2-1):

1.

6. The brain function-enhancing beverage composition containing brain peptide hydrolysate according to claim 1, characterized in that: The auxiliary materials include 0.3-0.5wt% of jujube seed composite powder, 0.4-0.6wt% of γ-aminobutyric acid and 0.02-0.06wt% of taurine; the stabilizer includes 2-5wt% of erythritol and 0.06-0.1wt% of xanthan gum; The additive consists of 0.05-012 wt % of food flavor, 0.015-0.021 wt % of nisin, and 0.003-0.009 wt % of sucralose.

7. The brain function-enhancing beverage composition containing brain peptide hydrolysate according to claim 1, characterized in that: The concentrated juice includes one or a combination of blueberry concentrated juice, apple concentrated juice, and lemon concentrated juice; The brain protease hydrolysate concentrate includes amino acids of the sequence Leu-Phe-Leu-Pro-Arg.

8. The brain function-enhancing beverage composition containing brain peptide hydrolysate according to claim 1, characterized in that: The total amount of the beverage composition is as follows: Brain protein hydrolysate concentrate 6wt%; Walnut peptide 1.04wt%; Intestinal peptide 0.02wt%; Stabilizer: The stabilizer is composed of 4wt% erythritol and 0.08wt% xanthan gum; Concentrated juice: blueberry concentrated juice 4wt%; Auxiliary materials: The auxiliary materials are composed of 0.4wt% of Suanzaorensis seed composite powder, 0.5wt% of γ-aminobutyric acid and 0.05wt% of taurine; Additives: The additives are composed of 0.08wt% food flavor, 0.019wt% nisin and 0.006wt% sucralose; Remaining amount of water.

9. A method for preparing a beverage composition containing brain peptide hydrolysate for improving brain function as described in any one of claims 1 to 8.

10. Use of a beverage composition containing brain peptide hydrolysate for improving brain function as claimed in any one of claims 1 to 8 in a functional beverage and / or medicine for treating brain damage.

Images